## Evaluation of a Scalable Design for a Pediatric Telemedicine and Medication Delivery Service: A Prospective Cohort Study in Haiti

#### Authors

Molly B. Klarman(MPH)<sup>1</sup>, Xiaofei Chi<sup>1</sup>(MS), Youseline Cajusma(BSN)<sup>1</sup>, Katelyn E. Flaherty(PhD)<sup>2,3</sup>, Jude Ronald Beausejour(MD)<sup>1</sup>, Lerby Exantus(MD)<sup>4</sup>, Valery M. Beau de Rochars(MD)<sup>5</sup>, Chantale Baril(MD)<sup>4</sup>, Torben K. Becker(MD, PhD)<sup>2,3</sup>, Matthew J. Gurka (PhD)<sup>6</sup>, Eric J. Nelson(MD, PhD)<sup>1,2\*</sup>

#### Affiliations

<sup>1</sup> Department of Pediatrics University of Florida, Gainesville, FL, USA

- <sup>2</sup> Department of Environmental and Global Health, University of Florida, Gainesville, FL, USA
- <sup>3</sup> Department of Emergency Medicine, University of Florida, Gainesville, FL, USA
- <sup>4</sup> Université d'État d'Haiti- Faculté de Médecine et de Pharmacie, Port-au-Prince, Haiti
- <sup>5</sup> Department of Health Services Research, Management and Policy, University of Florida, Gainesville, FL, USA
- <sup>6</sup> Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA
- \* Corresponding author

## **Corresponding author**

Eric J Nelson, MD PhD MS FAAP 2055 Mowry Road, Emerging Pathogens Institute, University of Florida Gainesville, FL 32611, (352) 294-8536 Email: <u>eric.nelson@ufl.edu</u>

Keywords: pediatrics, telemedicine, healthcare access, scaling

**Financial support:** This work was financially supported at the University of Florida by the Children's Miracle Network (EJN), private donations made to the University of Florida Foundation, and a National Institutes of Health grant (EJN).

**Conflict of interest:** The authors declare no reported conflicts. The funders had no role in the conduct or publication of the study.

**Prior submission and presentation of study data:** Portions of the data in this manuscript have been presented orally and by poster at the following conferences: The American Society of Tropical Medicine and Hygiene Annual Meeting 2021, 2022, 2024 and The University of Florida Pediatrics Research Day 2021, 2022, 2024.

**Data availability** De-identified data from this study are available from the corresponding author (EJN) upon request.

## 1 ABSTRACT

Objective. To evaluate a scalable pediatric telemedicine and medication delivery
 service (TMDS) that extends early healthcare access at households to avert
 emergencies.

5 Study design. A TMDS in Haiti was configured for scalability by triaging severe 6 cases to hospital-level care, non-severe cases with higher clinical uncertainty to in-7 person exams at households with medication delivery, and non-severe cases with low 8 clinical uncertainty to medication delivery alone. This design was evaluated in a 9 prospective cohort study conducted among pediatric patients (≤10 years). Clinical and 10 operational metrics were compared to a formative reference study in which all non-11 severe patients received an in-person exam. The primary outcomes were reported 12 rates of clinical improvement/recovery and in-person care seeking at 10-days. 13 **Results:** 1043 cases (41 severe; 1002 non-severe) were enrolled in the scalable 14 TMDS mode and 19% (190) of the non-severe cases received an in-person exam. 15 382 cases (24 severe, 358 non-severe) were enrolled in the reference study and 94% 16 (338) of the non-severe cases received an in-person exam. At 10-days, rates of 17 improvement were similar for the scalable (97%, 897) and reference (95%, 329) 18 modes. Rates of participants who sought follow-up care were 15% (138) in the 19 scalable mode and 24% (82) in the reference mode. 20 **Conclusion:** In the context of a five-fold reduction of in-person exams, participants in 21 the scalable TMDS mode had non-inferior rates of improvement at 10-days. These 22 findings highlight an innovative and now scalable solution to improve early access to 23 healthcare at households without compromising safety.

#### 24 INTRODUCTION

25 The World Health Organization (WHO) established the Integrated Management 26 for Childhood Illness (IMCI) guidelines for the management of sick children in 1995 (1, 27 2). The approach has since been deployed globally and is the current standard for 28 community-based pediatric care in low- and middle-income countries (LMIC) (3). There 29 are numerous challenges to successfully implement the IMCI strategy which limits its 30 potential to effectively reduce morbidity and mortality (4-8). Implementation science 31 frameworks have facilitated the design, evaluation and uptake of potential solutions to 32 address these complex challenges (9). These solutions include technologies aimed at 33 bridging the 'know-do gap', specifically the gap between knowledge of the IMCI 34 guidelines and effective implementation of the guidelines (10-14). 35 Despite these advances, there are gaps in the accessibility of IMCI adherent 36 clinics. We seek to close these gaps by extending early access to high-guality pre-37 emergency pediatric healthcare at the household level. We focus on the nighttime 38 when healthcare seeking is often delayed to the morning because of financial and 39 logistical barriers (15, 16). Delay raises the risk of developing life-threatening disease 40 that leads to higher-cost interventions (17, 18). In response, we designed and 41 implemented a pediatric telemedicine and medication delivery service (TMDS) that 42 uses clinical resources derived from the IMCI guidelines. 43 The TMDS model has been developed and rigorously evaluated within the 44 Improving Nighttime Access to Care and Treatment (INACT) study series. The INACT studies began in Haiti (15) and expanded to Ghana to test adaptability (16). In Haiti, 45

the INACT1-H study characterized care-seeking barriers (15). The INACT2-H study

47 was a pre-pilot that established clinical safety, feasibility and guideline performance of 48 a TMDS (19, 20). The study tested if 'what was heard' over the phone per virtual 49 exams matched 'what was seen' at the bedside per in-person exams. Severe cases 50 were referred to hospital-level care. All non-severe cases received paired virtual and 51 in-person exams to determine the accuracy of the virtual assessments and treatment 52 plans. This study identified high rates of improvement/recovery at 10-days (95%). The 53 evaluation of most non-severe cases had what we considered low clinical uncertainty 54 (see methods), and we hypothesized these cases could safely be managed with 55 medication delivery alone. However, a subset of cases had higher clinical uncertainty, 56 and we hypothesized these cases would require continued in-person evaluation. We 57 reasoned that configuring the TMDS to align with these hypotheses would reduce in-58 person exams by approximately 85% without compromising the high rates of 59 improvement/recovery.

60 The INACT3-H study, presented herein, aims to test our clinical guidelines, 61 hypotheses, and overall approach as a pathway to scalability. Within implementation 62 science frameworks for scaling(21), our approach addresses the facilitator; 'designing 63 the innovation for scale' (22, 23). In doing so, the primary design modification was 64 removing the clinical 'guardrail' of in-person exams for non-severe cases with low 65 clinical uncertainty. A secondary design modification was restructuring the TMDS into a 66 'hub and spoke' model where one central call center serviced multiple delivery zones. 67 These modifications are anticipated to reduce the financial and human resources required to operate a TMDS (24). Our approach was respectful of the challenges with 68 69 real-world implementation of novel innovations and the study protocol was permissive of

- 70 iterations. The scalable design was implemented within a prospective cohort study
- 71 (INACT3-H) and the results were compared to the prior published prospective cohort
- 72 study as a reference standard (INACT2-H).

73 METHODS

74 **Ethics statement.** The INACT3-H study and the previously published INACT2-H study

75 were reviewed and approved by the University of Florida Institutional Review Board

76 (IRB202002693; IRB201802920) as well as the Comité National de Bioéthique (National

77 Bioethics Committee of Haiti; Ref2021-11; Ref1819-51).

78 **Study design.** The INACT2-H and INACT3-H studies were prospective cohort studies.

79 The INACT2-H workflow was modified to facilitate scalability; the scalable mode was

80 deployed in the INACT3-H study. Outcomes from INACT3-H were compared to those

81 from INACT2-H (reference standard).

82 Study population and setting. INACT2-H was conducted in Gressier, Haiti. INACT3-H

83 was conducted in both Gressier and Les Cayes, Haiti. Gressier has a population of

36,400 and is characterized by rural mountainous regions and more densely populated

coastal communities(25). Les Cayes is approximately 175km west of Gressier. It has a

population of 152,000 people(25), and over half live in the urban center. On August 14,

87 2021, Les Cayes was impacted by a 7.2 magnitude earthquake that displaced

inhabitants and impacted population dynamics (26). Both Gressier and Les Cayes have

89 minimal public infrastructure (e.g., electricity, paved streets, reliable telecommunication

90 services). The study periods were marked by spikes of political and societal instability

91 that impacted the movement of goods and provision of services with detrimental effects

92 on health and healthcare(27, 28).

93 **Participant recruitment.** Participant populations were informed of the TMDS through 94 radio and print advertisements as well as announcements at schools and clinics. 95 Participant inclusion criteria and consent process. For both studies, children were 96 eligible to participate if their parent contacted the TMDS during operational hours (6 PM-97 5 AM) regarding an illness experienced by their child aged ≤10 years. Written consent 98 from parents/quardians, and assent from children  $\geq 7$  years, was obtained from families 99 who received an in-person exam. Parents/guardians whose only contact with the TMDS 100 was a virtual encounter were read a waiver of documentation of consent over the 101 phone. 102 **Enrollment.** Enrollment estimates for the scalable mode (INACT3-H) were based on 103 expected call volume that was established in the reference mode (INACT2-H). 104 Enrollment during INACT3-H was increased iteratively to assure that both research and 105 service objectives were met in response to dynamic national safety and logistical 106 challenges. 107 **Participant incentives and fees.** Across both studies, TMDS users were asked to pay 108 a fee of 500 Gourdes (5 USD) to contribute to the cost of delivery and medications. The 109 fee was reduced or waived for those who were unable to pay in full. 110 Implementation. 111 TMDS workflow. The workflow elements shared between the studies were as follows 112 (Figure 1); i) A parent contacted the call center and was connected to a provider. ii) The 113 provider gathered demographic and clinical information about the sick child, referenced 114 clinical resources, and generated a treatment plan that included triage classification 115 (mild, moderate, or severe), treatment location (hospital or home), recommended

116 medications and/or fluids, and advice on follow-up care. iii) Severe cases were 117 immediately referred to the hospital. iv) For non-severe cases, those residing in a 118 delivery zone received an in-person exam by a provider and/or delivery of 119 medications/fluids. v) Children residing outside a delivery zone, or who did not require 120 medications/fluids, received virtual advice alone. vi) Patients requiring hospital or 121 mandatory clinic follow-up received a 24-hour follow-up call. All patients received a 10-122 day follow-up call to ascertain the child's condition and feedback on the service. 123 TMDS elements specific to the reference mode (INACT2-H). The call center served a 124 single delivery zone in Gressier, Haiti. Call center providers performed in-person exams 125 for all non-severe cases within the delivery zone; the paired exams were used to assess 126 the accuracy of the virtual exams. TMDS workflow elements specific to the scalable mode (INACT3-H). The INACT2-H call 127

128 center and Gressier delivery zone were maintained and a second delivery zone in Les 129 Cayes, Haiti was added in response to humanitarian need caused by an earthquake. 130 The TMDS workflow was configured to reserve in-person exams for non-severe cases 131 with higher clinical uncertainty. Participant siblings of these cases also received in-132 person exams. For non-severe cases with low clinical uncertainty, delivery drivers were 133 dispatched to transport medications/fluids to participant households. We estimated this 134 change would limit in-person exams to approximately 15% of all cases. In the 'delivery-135 alone' situations, instructions on how to prepare and administer the medications/fluids 136 were relayed by the provider to the parent over the phone at the end of the virtual exam. 137 The information was reinforced through video tutorials that were played for parents on a

tablet at the household; parents were offered an opportunity to reconnect to call centerproviders for clarifications.

*Provider and staff training.* The providers were licensed Haitian nurses and nurse practitioners. Six of ten call center providers worked for the TMDS during both the INACT2-H and INACT3-H studies. Licensed Haitian physicians were available by phone to provide advice on cases outside the scope of the clinical resources. All providers and drivers received didactic and experiential training relative to their clinical, research, and operational responsibilities.

146 Clinical procedures, guidelines and resources. Providers were equipped with three 147 primary clinical resources to guide the virtual and in-person exams. These resources 148 are described elsewhere (29) and include: (i) A clinical guideline based on in-person 149 WHO pediatric resources and adapted for telemedicine use (Supplementary Text1). 150 The guideline prioritized six common childhood illnesses/problems: 'Fever', 151 'Respiratory problem/Cough', 'Dehydration'/'Vomit'/'Diarrhea', 'Ear pain', 'Skin 152 problem', 'Pain with urination' and 'Other'. Each section began with a summary of the 153 problem and was stratified by the diagnostic criteria used to triage the severity of the 154 problem into mild, moderate, or severe categories. Criteria that designated a case as 155 severe were referred to as 'danger signs'. Within each stratum there was guidance on 156 how to treat, where to treat, and when to follow-up. Directives on treatment location 157 were based on severity and clinical uncertainty. In regard to 'clinical uncertainty', a 158 strict definition is difficult to set and build into guidelines because it is the collective 159 impression the provider establishes based on both objective and subjective data. Our 160 guidelines were derived from IMCI guidelines which adhere to broad standards of

161 pediatric care and organically make recommendations based on degrees of 162 uncertainty. With this mindset, our guidelines prioritized in-person exams for patients 163 less than 1 year age, especially those with fever and/or concern for fever and cough, 164 as well as patients with concern for dehydration (e.g., 12+ episodes of diarrhea) or 165 concerns for respiratory insufficiency (e.g., fast breathing). These conditions are 166 associated with high clinical uncertainty as they often present subtly, yet are 167 vulnerable to progressive decompensation, specifically from sepsis, pneumonia, and 168 hypovolemic shock, respectively. (ii) A paper case report form that guided data 169 collection during virtual and in-person exams and was embedded with clinical 170 decision support (Supplementary Text2). (iii) A medication formulary that outlined 171 available medications/fluids and dosing recommendations (Supplementary Text3). 172 These resources have been iterated and adapted to real-world use since they were 173 first piloted in September 2019. The resources were written for mid-level healthcare 174 providers (e.g., experienced nurses, nurse-practitioners). While the guidelines did not 175 explicitly state when a case scenario has higher versus low clinical uncertainty, 176 uncertainty is built into the algorithms, which follow WHO standards of practice(2, 30). 177 The WHO standards are based in part on risk stratifications set by consensus-based 178 expert opinion or evidence-based primary clinical research studies. The clinical 179 guidelines and resources remain intended for use in this INACT study series alone. 180 Outcome measures. 181 *Primary.* The primary outcome measures were rates of improvement/recovery and rates

182 of in-person care seeking at 10-day follow-up.

183 Secondary. Secondary outcome measures consisted of operational, performance and 184 10-day feedback components. Operational measures were 'virtual exam duration' 185 defined as the length of time to complete a virtual exam over the phone and 'time to 186 arrival at household' defined as the length of time spanning from initial contact with the 187 TMDS by phone until a driver (with or without provider) arrived at the participant's 188 house. Performance measures focused on congruence and guideline deviations. 189 Congruence refers to the agreement between components of the paired virtual and in-190 person exams; congruence was assessed for case severity, presence of fever, fast 191 breathing, and dehydration, and treatment with select medications. Guideline deviations 192 were instances when a provider made a clinical decision outside the scope of the 193 written clinical guidelines. Deviations were expected and may have occurred due to 194 human error, situational adaptability, or direction from the oversight physician. 195 Deviations were quantified for danger signs and select medications provided. User 196 feedback was obtained in structured (Likert scale) and unstructured (free text) formats. 197 Exploratory. Analyses were stratified by type of care provided and delivery zone 198 location. 199 Data analysis. Clinical, operational, and performance outcome measures were 200 compared between the scalable (INACT3-H) and reference (INACT2-H) modes. 201 Analytic strategy. Repeat cases within 30 days were excluded from both study cohorts. 202 Participants not reached at the 10-day follow-up were excluded from the clinical

203 outcome and feedback analyses. Missing data for other variables was addressed

through pairwise deletion. In the scalable mode guideline deviations were identified by

205 internally reviewing the data for instances of missed danger signs and accuracy of

206 medications included in treatment plans (e.g., complaints of pus in ear should yield 207 inclusion of amoxicillin in plan). The identification of guideline deviations occurring in the 208 reference mode was described previously(19). When calculating guideline deviation 209 rates, the number of completed exams (virtual and in-person) was used as the unit of 210 analysis. Congruence was assessed for the subset of cases that had paired virtual and 211 in-person exams which mainly included cases with higher clinical uncertainty. 212 Comparisons that involved a guideline deviation were excluded from the respective 213 congruence analyses. Medications included in the congruence analyses were selected 214 because of their centrality to the clinical guidelines and were provided most frequently. 215 Statistical analysis. Proportions were used to describe categorical variables and 216 medians with interguartile ranges were used to describe continuous variables. To test 217 differences between the modes (scalable and reference) or between locations within 218 the scalable mode (Gressier and Les Cayes), Chi-square tests or Fisher's exact tests 219 were used for nominal variables, Cochran-Armitage Trend tests for ordinal variables, 220 and two-sample t-tests for continuous variables. To compare clinical and operational 221 outcomes between the two modes stratified by type of care provided, Cochran-222 Mantel-Haenszel tests (General Association) were used for nominal variables, 223 Cochran-Mantel-Haenszel tests (Row Mean Scores Differ) for ordinal variables, and 224 two-way ANOVA for continuous variables. Binary assessments were described using 225 Cohen's kappa, sensitivity, specificity, positive predictive values (PPV), and negative 226 predictive values (NPV). Assessments with kappa values were classified as follows: -227 0.1 – 0.20 'no agreement', 0.21 – 0.39 'minimal', 0.40 – 0.59 'weak', 0.60 – 0.79

<sup>228</sup> 'moderate', 0.80 – 0.90 'strong', and >0.90 'almost perfect'(31). Analyses were

229 completed using Statistical Analysis Software (SAS Institute) V.9.4.

230 **RESULTS** 

231 Participant and case characteristics. The reference mode enrolled 391 participants 232 from September 9, 2019, to January 19, 2021 and the scalable mode enrolled 1068 233 participants from January 20, 2021 to September 21, 2022. Among enrolled 234 participants, 1043 from the scalable mode and 382 from the reference mode were 235 included in the analyses (Figure 2). The median age was 24 months (IQR 12-48 236 scalable; 9-48 reference;) for both cohorts, sex distributions were similar (Table 1). 237 There was a lower proportion of participants aged <2 months in the scalable cohort (1%, 238 15) compared to the reference cohort (7%, 26). The chief and general complaints were 239 similar among both modes. The most prevalent chief complaint was 'fever' (33%, 342) 240 scalable; 42%, 159 reference) followed by 'respiratory problem' (24%, 247 scalable; 241 17%, 67 reference), whereas the most prevalent general complaint was 'respiratory 242 problem' (66%, 686 scalable; 65%, 247 reference), followed by 'fever' (55%, 576 243 scalable; 55%, 212 reference). Virtual complaints of 'fever' were determined subjectively 244 in all but 7 cases (1, 1% scalable; 6, 3% reference). Gastrointestinal and dermatologic 245 complaints were also common. Based on the virtual exams, approximately three-fourths 246 of cases were triaged as mild in both the scalable (76%, 788) and reference (73%, 278) 247 modes. In the scalable mode, 18% (190) of cases received a virtual exam and an in-248 person exam with delivery and 73% (760) received a virtual exam with delivery. In the 249 reference mode, 88% (338) of cases received a virtual and an in-person exam with 250 delivery. The proportion of cases that received a virtual exam alone (no in-person exam

or delivery) because of hospital referral or workflow constraint (e.g., caller was outside
delivery zone) was similar between the scalable (9%, 93) and reference (12%, 44)
modes.

254 **Primary outcomes.** In the scalable mode, the rate of participants with a clinical status

of improved/recovered was 97% (897) and in the reference mode the rate was 95%

(329). No mortalities occurred in the scalable mode, and one occurred in the reference

mode. At the 10-day follow up 15% (138) of participants in the scalable mode had

sought care and 24% (82) of participants in the reference mode had sought care (Table

259 **2**).

Secondary outcomes. The median call duration was 16 mins (IQR 12-20 mins) in the scalable mode and 20 mins (IQR 15-25 mins) in the reference mode. The median time to household arrival was 73 mins (IQR 56-102 mins) in the scalable mode and 78 mins (IQR 62-104 mins) in the reference mode.

264 The aggregate rate of guideline deviations was 5% (63) in the scalable mode and 265 11% (82) in the reference mode (Table 3). Rates of missed danger signs were 1% (11) 266 in the scalable mode compared to 2% in the reference mode; a misinterpreted 267 respiratory rate was the most frequent danger sign deviation. Events of medications 268 provided (most commonly amoxicillin) that were not indicated occurred in 1% (18) of 269 cases in the scalable mode and 3% (19) in the reference mode. Events of indicated 270 medications (most commonly zinc) that were not provided occurred in 3% (34) of cases 271 treated in the scalable mode and 7% (52) in the reference mode.

272 In the scalable mode congruence was evaluated for the subset of cases that had 273 paired virtual and in-person exams. In this context, the Cohen's kappa value for cases

274 virtually triaged as mild was minimal at 0.22 (95% CI 0.07-0.38) (Table S1); in the 275 reference mode it was 0.78 (95% CI 0.69-0.87). The kappa value for cases virtually 276 triaged as moderate was 0.25 (0.10-0.41); in the reference mode it was 0.78 (95% CI 277 0.69-0.87). A similar approach was taken to evaluate select components of the virtual 278 exam. The assessment of fever had a kappa value of 0.24 (95%CI 0.12-0.35); in the 279 reference mode, the corresponding kappa value was 0.58 (95%CI 0.49-0.66). The 280 assessment of fast breathing was not congruent with measured rates during the in-281 person exam; minimal congruence was observed in the reference mode. The 282 assessment of dehydration during the virtual exam had minimal agreement (kappa 0.24; 283 95%CI 0.01-0.47); in the reference mode there was moderate agreement (kappa 0.69; 284 95%CI 0.41-0.98). Despite low congruence, aspects of the virtual exam had high performance metrics (sensitivity, specificity, PPV, NPV) of over 90%. Agreement 285 286 between medication recommendations based on paired virtual and in-person exams 287 was also assessed. In the scalable mode, paracetamol and amoxicillin exhibited 288 minimal (kappa 0.35; 95%CI 0.22-0.48) and weak (0.47 95% CI 0.35-0.58) agreement, 289 respectively. Benzyl benzoate (0.66 95%CI 0.49-0.83), cephalexin (0.62 95%CI 0.38-290 0.85) and zinc (0.62 95%CI 0.48-0.75) exhibited moderate congruence. These 291 measures were consistently lower in the scalable mode than the reference mode. 292 Feedback. Participants from the scalable mode rated the service as 'great' (highest 293 Likert scale response) at a rate of 92% (859) compared to 86% (300) in the reference 294 mode (Table 2).

Exploratory. Stratified analyses were performed for both the scalable and reference
 modes as an exploratory step to evaluate how the type of care provided (virtual exam

297 alone; virtual exam and in-person exam with delivery; virtual exam with delivery) 298 impacted primary and secondary outcome measures. Within both modes, participants 299 who received virtual exams with delivery (with or without in-person exams) had similar 300 rates of improvement/recovery, care seeking, and feedback assessed as 'great'. The 301 relatively few cases in both the scalable and reference modes who received virtual 302 exams alone without delivery had less favorable outcomes for clinical status, care-303 seeking and feedback at 10-days (Table 4). Given that the scalable mode included a 304 second delivery zone, we conducted analyses to compare outcome measures between 305 the two sites. Clinical status, rates of care seeking and feedback at the 10-day follow-up 306 were similar between the delivery zones (Table S2). However, compared to Gressier, 307 cases in Les Cayes more commonly sought follow-up care from a hospital and the 308 median time to household arrival was longer.

#### 309 **DISCUSSION**

310 We compared a scalable mode of a TMDS that reserved in-person exams for non-311 severe cases with higher clinical uncertainty to a reference mode that required in-312 person exams for all non-severe cases; severe cases in both modes were referred to 313 hospital-level care. Pediatric patients were prospectively enrolled in two cohort studies 314 at different time periods to evaluate and compare the two modes. The primary outcome 315 measures were clinical status and rate of in-person care seeking at 10-days. In the 316 context of a five-fold reduction of in-person exams between the scalable and reference 317 modes, rates of improvement/recovery and in-person care seeking at 10-days were 318 similar for the scalable mode. These clinical findings, complemented by similar

operational and feedback metrics, represent a critical step towards a scalable solution
to improve early access to pediatric healthcare without compromising safety.

321 The implementation of the INACT studies in Haiti required an adaptative 322 approach to real-world events (e.g., natural disasters, political collapse, insecurity) that 323 in some ways increased the generalizability of the study series to other communities 324 faced with similar challenges. Safety of patients, providers and research staff were 325 prioritized at all times. With this mindset, the design of the reference study required in-326 person exams at households for all non-severe cases as a clinical 'quardrail'. This 327 requirement enabled the reference study (INACT2-H) to focus on feasibility, safety, and 328 guideline development/validation(19, 29). In this context we used congruence analyses 329 to evaluate the paired virtual and in-person exams. The analyses exposed anticipated 330 limitations with virtual exams that might leave providers with higher or lower clinical 331 uncertainty depending on the clinical scenario. The clinical guidelines were developed 332 to accommodate for this challenge. For the INACT3-H study, we hypothesized that 333 safety would not be compromised if the 'guardrail' of in-person exams was removed for 334 cases with low clinical uncertainty and maintained for cases with higher clinical 335 uncertainty. The results support this hypothesis, thus marking a critical step towards 336 scalability.

Among cases with higher clinical uncertainty that required in-person exams in the scalable mode, there was minimal/weak congruence between the virtual and in-person exams. This finding contrasts the reference study where congruence was higher. The difference was expected as the paired cases in the scalable mode had a higher degree of clinical uncertainty than those in the reference mode by design. Taken together the

342 results support the need for continued in-person exams for cases with higher clinical 343 uncertainty. Exploratory analyses characterized the subset of participants who received 344 a virtual exam with delivery because this group received less contact with a provider 345 compared to those that received a virtual exam and an in-person exam with delivery. 346 Similar clinical outcomes and feedback scores were observed between these two 347 groups. These data suggest a non-inferior patient experience for those cases that 348 received virtual exams with delivery. The small subset of participants who received a 349 virtual exam alone (no in-person encounter by provider or delivery driver) may have had 350 inferior outcomes in terms of clinical status and feedback at 10-days. This finding is not 351 unexpected considering these participants received advice only without provided 352 medication.

353 One impactful 'real-world' event was an earthquake that occurred southwest of 354 the Gressier site soon after initiating the scalable mode (32). For humanitarian reasons, 355 a delivery zone in Les Cayes was added which required an additional step of relaying 356 virtual treatment plans from the Gressier call center to on-call providers in Les Cayes. 357 This adaptation could represent a potential study limitation, however stratification by 358 study site yielded similar outcomes between the two delivery zones. The rate of care 359 seeking at the hospital level was higher in Les Cayes, likely due to increased hospital 360 access within the delivery zone. Les Cayes participants also experienced a longer 361 median time to household arrival that was likely caused by to the need to mobilize the 362 on-call provider; the road network in Les Cayes is better and may have mitigated the 363 extent of the longer arrival time.

364 The results from this study should be viewed within the context of the following additional limitations: (i) Virtual treatment plans only addressed complaints that parents 365 366 chose to report. In contrast, in-person treatment plans addressed all problems identified 367 by the provider, allowing virtual and in-person plans to be based on different problems. 368 This factor limited the treatment plan congruence analyses. ii) The clinical resources 369 have undergone minor iterations throughout both study periods. Therefore, the 370 treatment plans were not absolutely equivalent at all points. In addition, we did not 371 control for increased provider expertise over the study period. iii) The environment in 372 which both studies were conducted was volatile which may have confounded 373 enrollment, operational outcomes, and disease severity over time. iv) The primary 374 outcome measures were based on parent reports from the 10-day follow-up call and 375 therefore is at risk of response and recall bias. Despite these limitations, the study 376 provides evidence to justify a transition to the scalable mode.

#### 377 CONCLUSIONS

378 Early access to healthcare is essential to avert morbidity and mortality. However, 379 innovative strategies are needed to assure early access to care, especially when 380 patients are isolated by geography, poverty or illness that presents 'off-hours'. A 381 telemedicine and medication delivery service (TMDS) represents an innovative 382 solution to extend care to these vulnerable populations. We evaluated a scalable 383 design for a pediatric TMDS for low-resource settings that triaged severe cases to 384 hospital-level care, non-severe cases with higher clinical uncertainty to in-person 385 exams at households with medication delivery, and non-severe cases with low clinical 386 uncertainty to medication delivery alone. We found that within the context of a five-387 fold reduction of in-person exams, participants in the scalable mode had non-inferior

- 388 rates of improvement/recovery and care-seeking. Future steps towards scaling will be
- to digitize the TMDS clinical resources, implement this digital tool within the scalable
- 390 TMDS workflow and evaluate outcomes.
- 391
- 392
- 393

### 394 Acknowledgements

- 395 We would like to thank both the INACT3-H and INACT2-H study participants and the
- 396 TMDS employees. We are grateful to the University of Florida Department of Pediatrics
- 397 administrators, Randy Autrey, Krista Berquist and Brittney Johnson. We express our
- 398 appreciation for the academic support provided by Glenn Morris at the Emerging
- 399 Pathogens Institute and Rashmin Savani Chair of the Department of Pediatrics. Finally,
- 400 we value our partnership with the Ministry of Public Health and Population (Ministère de
- 401 la Santé Publique et de la Population MSPP).

# 403 **REFERENCES**

- 404 Gove S. Integrated management of childhood illness by outpatient health workers: 1. 405 technical basis and overview. The WHO Working Group on Guidelines for Integrated 406 Management of the Sick Child. Bull World Health Organ. 1997;75 Suppl 1(Suppl 1):7-24. 407 2. World Health Organization. Handbook: IMCI Integrated Management of Childhood 408 Illness Geneva Switzerland2000 [Available from: https://apps.who.int/iris/bitstream/handle/10665/104772/9789241506823 Module-409 410 1\_eng.pdf?sequence=3. 411 Boschi-Pinto C, Labadie G, Dilip TR, Oliphant N, Dalglish SL, Aboubaker S, et al. 3. 412 Global implementation survey of Integrated Management of Childhood Illness (IMCI): 20 years 413 on. BMJ Open. 2018;8(7):e019079. 414 Kiplagat A, Musto R, Mwizamholya D, Morona D. Factors influencing the 4. 415 implementation of integrated management of childhood illness (IMCI) by healthcare workers at 416 public health centers & dispensaries in Mwanza, Tanzania. BMC Public Health. 2014;14:277. 417 Kim K, Helena H, Albert D, Beatiwel Z, Lumbani B, Josephine L, et al. Integrated 5. 418 Management of Childhood Illnesses (IMCI): a mixed-methods study on implementation, 419 knowledge and resource availability in Malawi. BMJ Paediatrics Open. 2021;5(1):e001044. 420 Bryce J, Victora CG, Habicht JP, Black RE, Scherpbier RW. Programmatic pathways to 6. 421 child survival: results of a multi-country evaluation of Integrated Management of Childhood 422 Illness. Health Policy Plan. 2005;20 Suppl 1:i5-i17. 423 Carai S, Kuttumuratova A, Boderscova L, Khachatryan H, Lejnev I, Monolbaev K, et al. 7. 424 Review of Integrated Management of Childhood Illness (IMCI) in 16 countries in Central Asia 425 and Europe: implications for primary healthcare in the era of universal health coverage. (1468-426 2044 (Electronic)). 427 Reñosa MA-O, Dalglish SA-O, Bärnighausen KA-O, McMahon S. Key challenges of 8. 428 health care workers in implementing the integrated management of childhood illnesses (IMCI) 429 program: a scoping review. (1654-9880 (Electronic)). 430 Bauer MS, Kirchner J. Implementation science: What is it and why should I care? 9. 431 Psychiatry Research. 2020;283:112376. 432 Sarrassat S, Lewis JJ, Some AS, Somda S, Cousens S, Blanchet K. An Integrated 10. eDiagnosis Approach (IeDA) versus standard IMCI for assessing and managing childhood 433 434 illness in Burkina Faso: a stepped-wedge cluster randomised trial. BMC Health Serv Res. 435 2021;21(1):354. 436 Mitchell M, Hedt-Gauthier BL, Msellemu D, Nkaka M, Lesh N. Using electronic 11. 437 technology to improve clinical care – results from a before-after cluster trial to evaluate 438 assessment and classification of sick children according to Integrated Management of Childhood 439 Illness (IMCI) protocol in Tanzania. BMC Medical Informatics and Decision Making. 440 2013;13(1):95. 441 12. Schmitz T, Beynon F, Musard C, Kwiatkowski M, Landi M, Ishaya D, et al. 442 Effectiveness of an electronic clinical decision support system in improving the management of 443 childhood illness in primary care in rural Nigeria: an observational study. BMJ Open. 444 2022;12(7):e055315. 445 Beynon F, Guérin F, Lampariello R, Schmitz T, Tan R, Ratanaprayul N, et al. 13. 446 Digitalizing Clinical Guidelines: Experiences in the Development of Clinical Decision Support 447 Algorithms for Management of Childhood Illness in Resource-Constrained Settings. Global
- 448 Health: Science and Practice. 2023;11(4):e2200439.


449 14. Jensen C, McKerrow NA-O, Wills GA-OX. Acceptability and uptake of an electronic


decision-making tool to support the implementation of IMCI in primary healthcare facilities in
KwaZulu-Natal, South Africa. (2046-9055 (Electronic)).

- 452 15. Klarman M, Schon J, Cajusma Y, Maples S, Beau de Rochars VEM, Baril C, et al.
  453 Opportunities to catalyse improved healthcare access in pluralistic systems: a cross-sectional
- 454 study in Haiti. BMJ Open. 2021;11(11):e047367.
- 455 16. Flaherty KE, Klarman MB, Zakariah AN, Mahama MN, Osei-Ampofo M, Nelson EJ, et
- 456 al. Evaluating the prerequisites for adapting a paediatric nighttime telemedicine and medication
- 457 delivery service to a setting with high malarial burden: A cross-sectional pre-implementation
- 458 study. Trop Med Int Health. 2023;28(9):763-70.
- 459 17. Update: outbreak of cholera ---Haiti, 2010. (1545-861X (Electronic)).
- 460 18. Sack DA, Sack Rb Fau Nair GB, Nair Gb Fau Siddique AK, Siddique AK. Cholera.
  461 (1474-547X (Electronic)).
- 462 19. Klarman MB, Flaherty KE, Chi X, Cajusma Y, Capois AC, Vladimir Dofiné MD, et al.
- 463 Implementation of a pediatric telemedicine and medication delivery service in a resource-limited 464 setting: A pilot study for clinical safety and feasibility. The Journal of Pediatrics. 2022.
- 465 20. Molly BK, Xiaofei C, Youseline C, Katelyn EF, Anne Carine C, Michel Daryl Vladimir
- 466 D, et al. Development and Evaluation of a Clinical Guideline for a Pediatric Telemedicine and
- 467 Medication Delivery Service: A Prospective Cohort Study in Haiti. medRxiv.
- 468 2023:2023.02.15.23285858.
- Trisha G, Chrysanthi P. Spreading and scaling up innovation and improvement. BMJ.
  2019;365:12068.
- 471 22. Spicer N, Hamza YA, Berhanu D, Gautham M, Schellenberg J, Tadesse F, et al. 'The
- 472 development sector is a graveyard of pilot projects!' Six critical actions for externally funded
- implementers to foster scale-up of maternal and newborn health innovations in low and middle-income countries. Globalization and Health. 2018;14(1):74.
- 4/4 income countries. Globalization and Health. 2018;14(1):74.
  475 23. Spicer N, Bhattacharya D, Dimka R, Fanta F, Mangham-Jeff
- 475 23. Spicer N, Bhattacharya D, Dimka R, Fanta F, Mangham-Jefferies L, Schellenberg J, et al.
  476 'Scaling-up is a craft not a science': Catalysing scale-up of health innovations in Ethiopia, India
  477 and Nigeria. Social Science & Medicine. 2014;121:30-8.
- 478 24. Flaherty KE, Klarman MB, Cajusma Y, Schon J, Exantus L, Beau de Rochars VM, et al.
- 479 A Nighttime Telemedicine and Medication Delivery Service to Avert Pediatric Emergencies in
- 480 Haiti: An Exploratory Cost-Effectiveness Analysis. The American Journal of Tropical Medicine481 and Hygiene. 2022;106(4):1063-71.
- 482 25. Direction Des Statistiques Démographiques Et Sociales. Population Totale, De 18 Ans Et
  483 Plus. Menages Et Densities Estimes En 2015.; 2015.
- 484 26. Eberle C. Technical Report: Haiti earthquake 2021/2022: United Nations University -
- Institute for Environment and Human Security (UNU-EHS); 2022 [Available from:
   http://collections.unu.edu/view/UNU:9022#viewMetadata.
- 487 27. Taylor L. Haiti's hospitals plan to close amid fuel shortages. Bmj. 2022;379:o2379.
- 488 28. Severe K, Alcenat N, Rouzier V. Resurgence of Cholera in Haiti amidst Humanitarian
  489 Crises. N Engl J Med. 2022.
- 490 29. Klarman MB, Chi X, Cajusma Y, Flaherty KE, Capois AC, Dofiné MDV, et al.
- 491 Development and Evaluation of a Clinical Guideline for a Pediatric Telemedicine and
- 492 Medication Delivery Service: A Prospective Cohort Study in Haiti. medRxiv.
- 493 2023:2023.02.15.23285858.

- 494 30. World Health Organization. Pocket book of hospital care for children: Second edition
- 495 Geneva, Switzerland2013 [Available from: https://www.who.int/publications/i/item/978-92-4-
- 496 <u>154837-3</u>.
- 497 31. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb).
- 498 2012;22(3):276-82.
- 499 32. Daniels JP. Earthquake compounds Haiti's health challenges. The Lancet.
- 500 2021;398(10304):944-5.

**Figure 1.** General workflow of a telemedicine and medication delivery service (TMDS). The parent of a sick child contacts the call center. A provider receives the call and performs a virtual exam by asking the parent targeted questions about the child and their specific symptoms. The provider references clinical resources to create a treatment plan based on illness severity that includes disposition, medications/fluids, and follow-up recommendations. Families are contacted by phone at 10 days; severe cases are also contacted at 24 hours. In the reference mode (INACT2H) all non-severe cases residing within the delivery zone received a paired in-person exam at the household to compare evaluate the quality of virtual exams to the in-person exams.





**Figure 2.** Diagram of case enrollment and inclusion in analyses for scalable and reference Telemedicine and Medication Delivery Service (TMDS) modes.

Characteristic	Scalable mode	Reference mode	
Characteristic	(n=1043) <sup>a</sup>	(n=382) <sup>b</sup>	
Participant age, median mos (Q1-Q3) <sup>c</sup>	24 (12-48)	24 (9-48)	
<2 mos	15 (1%)	26 (7%)	
2 mos to <2 yrs	417 (40%)	164 (43%)	
2 yrs to <5 yrs	374 (36%)	118 (31%)	
5 yrs to 10 yrs	237 (23%)	74 (19%)	
Participant sex; female	496 (48%)	178 (47%)	
Participant chief complaint <sup>d</sup>			
Fever	342 (33%)	159 (42%)	
Respiratory	247 (24%)	67 (17%)	
Gastrointestinal	109 (10%)	58 (15%)	
Dermatologic	237 (23%)	56 (15%)	
Other	108 (10%)	42 (11%)	
Participant complaints general <sup>d,e</sup>			
Fever	576 (55%)	212 (55%)	
Respiratory	686 (66%)	247 (65%)	
Gastrointestinal	337 (32%)	137 (36%)	
Dermatologic	383 (37%)	100 (26%)	
Case severity at call center			
Mild	788 (76%)	278 (73%)	
Moderate	214 (21%)	80 (21%)	
Severe	41 (4%)	24 (6%)	
Type of care provided			
Virtual exam and in-person exam with delivery	190 <sup>f</sup> (18%)	338 (88%)	
Virtual exam with delivery	760 (73%)	0	
Virtual exam alone	93 (9%)	44 (12%)	

Table 1. Characteristics of participants and cases enrolled in the scalable (INACT3-H) and reference (INACT2-H) modes.

<sup>a</sup> 25 repeat patients within 30 days were excluded.

<sup>b</sup> 9 repeat patients within 30 days were excluded.

 $^{c}$  (Q1-Q3) = Quartile 1 to quartile 3.

<sup>d</sup> The four most common complaints are represented.

<sup>e</sup> Multiple complaints per participant were permitted.

<sup>f</sup>19 mild and 3 moderate cases were triaged for delivery but received in-person exams.

	Scalable mode	Scalable mode Reference mode		
	(n=930 <sup>a</sup> )	(n=348 <sup>b</sup> )	p-value <sup>c</sup>	
Clinical status at 10-day follow-up <sup>a</sup>			.0374	
Improved/Recovered	897 (97%)	329 (95%)		
Same	26 (3%)	18 (5%)		
Worse	6 (1%)	1 (<1%)		
Care sought by 10-day follow-up (any)	138 (15%)	82 (24%)	.0002	
Type of care sought				
Hospital	75 (54%)	21 (26%)	<.0001	
Clinic	63 (46%)	55 (67%)		
Other	0	6 (7%)		
Mortalities	0	1 (<1%)		
Feedback on the TMDS service at the 10-day follow up			.0022	
Great	859 (92%)	300 (86%)		
Good	68 (7%)	44 (13%)		
Okay	3 (<1%)	2 (1%)		
Virtual exam duration (median minutes, Q1-Q3) <sup>d</sup>	16 (12-20)	20 (15-25)	<.0001	
Time to arrival at household (median minutes, Q1-Q3) <sup>d</sup>	78 (62-104)	73 (56-102)	.1722	

Table 2. Comparison of clinical and operational outcomes between the scalable (INACT3-H) and reference (INACT2-H) modes.

<sup>b</sup>34 participants were not reached at follow up

<sup>c</sup>See statistical analysis section in methods

<sup>d</sup>(Q1-Q3) = quartile 1 to quartile 3

Telefence (INACTZ-II) modes.				
Type of guideline deviation	Scalable	Reference	p-value	
	mode	mode	-	
Total deviations (all types)	63 (5%)	82 (11%)	<.0001	
Danger sign present but not identified (any)	11 (1%)	11 (2%)	.1991	
General WHO <sup>b</sup>	0	1 (<1%)	.0262	
Fever (<2 yrs)	0	2 (<1%)		
Respiration rate	4 (<1%)	6 (1%)		
Heart rate	7 (1%)	1 (<1%)		
Oxygen saturation <sup>c</sup>	0	1 (<1%)		
Provided medication <sup>d</sup> when not indicated (any)	18 (1%)	19 (3%)	.0652	
Amoxicillin	9 (1%)	17 (2%)	.0008	
Benzyl benzoate	0	0		
Cephalexin	0	0		
Doxycycline	0	0		
Erythromycin	0	2 (<1%)		
Paracetamol	7 (<1%)	0		
Zinc	2 (<1%)	0		
Did not provide medication <sup>d</sup> when indicated (any)	34 (3%)	52 (7%)	<.0001	
Amoxicillin	0	2 (<1%)	.0095	
Benzyl benzoate	2 (<1%)	0		
Cephalexin	0	0		
Doxycycline	0	0		
Erythromycin	3 (<1%)	0		
Paracetamol	0	0		
Zinc	29 (3%)	50 (7%)		

Table 3. Comparison of guideline deviations between the scalable (INACT3-H) and reference (INACT2-H) modes.

<sup>a</sup>Each virtual and in-person encounter is represented independently.

<sup>b</sup>Lethargic, convulsions, unable to drink/breastfeed<sup>.</sup>

<sup>c</sup> Oxygen saturation was evaluated during in-person exams only.

<sup>d</sup> The most frequently used medications are included.

Table 4. Comparison of clinical and operational outcomes stratified by type of care provided between the scalable (INACT3-H) and the reference (INACT2-H) modes.

	Scalable mode			Reference mode			
	Virtual exam and in- person exam with delivery (n=167)	Virtual exam with delivery (n=684)	Virtual exam alone (n=79)	Virtual exam and in- person exam with delivery (n=304)	Virtual exam with delivery (n=0)	Virtual exam alone (n=44)	p-value
Clinical status at 10-day follow-up							.2714
Improved/Recovered	161 (96%)	666 (97%)	70 (89%)	289 (95%)		40 (91%)	
Same	4 (2%)	14 (2%)	8 (10%)	14 (5%)		4 (9%)	
Worse	1 (1%)	4 (1%)	1 (1%)	1 (<1%)		0	
Care sought by 10-day follow-up (any)	21 (13%)	76 (11%)	44 (55%)	53 (17%)		30 (68%)	.471
Type of care sought							
Hospital	12 (7%)	37 (5%)	26 (33%)	13 (4%)		8 (18%)	<.0001
Clinic	9 (5%)	36 (5%)	18 (23%)	35 (12%)		20 (45%)	
Other				4 (1%)		2 (5%)	
Mortalities	0	0	0	1 (<1%)		0	
Feedback on TMDS service at 10-day follow-up							.0005
Great	160 (96%)	631 (92%)	68 (86%)	273 (90%)		27 (63%)	
Good	7 (4%)	51 (7%)	10 (13%)	29 (10%)		15 (35%)	
Okay	0	2 (<1%)	1 (1%)	1 (<1%)		1 (2%)	
Virtual exam duration (median minutes, Q1-Q3) <sup>a</sup>	18 (14-21)	15 (12-17)	17 (10-20)	20 (15-25)		20 (15-24)	<.0001
Time to arrival at household (median minutes, Q1-Q3) <sup>a</sup>	81 (65-108)	76 (61-103)		73 (56-102)			.0892

<sup>a</sup>(Q1-Q3) = quartile 1 to quartile 3